tradingkey.logo
tradingkey.logo

Indivior PLC

INDV
View Detailed Chart
28.790USD
-0.600-2.04%
Close 03/24, 16:00ETQuotes delayed by 15 min
3.60BMarket Cap
29.27P/E TTM

Indivior PLC

28.790
-0.600-2.04%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.04%

5 Days

-8.11%

1 Month

-12.92%

6 Months

+26.00%

Year to Date

-19.76%

1 Year

+185.05%

View Detailed Chart

TradingKey Stock Score of Indivior PLC

Currency: USD Updated: 2026-03-24

Key Insights

Indivior PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 157 in the Pharmaceuticals industry.Institutional ownership is very low.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.86.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Indivior PLC's Score

Industry at a Glance

Industry Ranking
55 / 157
Overall Ranking
162 / 4547
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Indivior PLC Highlights

StrengthsRisks
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.85% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 29.27, at a medium 3-year percentile range.
Held by HACAX
Star Investor HACAX holds 1.03K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
46.857
Target Price
+59.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Indivior PLC News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Indivior PLC Info

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Ticker SymbolINDV
CompanyIndivior PLC
CEOCiaffoni (Joseph J)
Websitehttps://www.indivior.com/en
KeyAI